Somatostatin and octreotide Somatostatin is a 14 amino acid peptide that was found to reduce splanchnic blood flow in normal humans. [29] [30] [31] In stable cirrhotic patients modest reductions in hepatic blood flow32 and wedged venous pressure33-36 have been reported by several groups, but others have found no effect on portal pressure32 37 or intravariceal pressure.38 Azygos blood flow, a measure of collateral blood flow including variceal flow, has, however, always been shown to fall with somatostatin, and more noticeably than with vasopressin for a similar reduction in portal pressure. 36 Octreotide is a synthetic octapeptide of somatostatin (sharing four amino acids with somatostatin that are responsible for biological activity), which has similar pharmacological effects as the naturally occurring hormone but a considerably longer duration of action. Like somatostatin, octreotide significantly reduces portal pressure in experimental animals39 40 and in patients with portal hypertension4l 42 after either an intravenous bolus administration or a continuous infusion. Subcutaneous administration produces a sustained reduction in portal pressure in rats with cirrhosis and portal hypertension.39 Perhaps more importantly with respect to the control of the acute variceal bleed, the effects of octreotide on collateral blood flow40 and azygos blood flow43 are significantly greater than its effect on portal pressure in experimental animals and patients with cirrhosis and portal hypertension.
Octreotide has similar effects to somatostatin in stable cirrhotic patients (not bleeding), with little or no effect on wedged hepatic venous pressure,44 45 The variability in splanchnic haemodynamic effects, particularly for portal pressure reduction, have led most clinicians to consider somatostatin or octreotide as unlikely therapeutic candidates to treat variceal bleeding. Although the reduction in azygos blood flow may be the important haemodynamic effect for the control of variceal bleeding, there is no proof that this is so. The effects on splanchnic haemodynamics, however, should be tempered by several considerations when considering the results of therapeutic efficacy in various trials of vasoactive drugs in portal hypertension. Firstly, in cirrhotic patients the variability in splanchnic haemodynamic effects in response to any vasoactive drug probably reflects normal biological variability or possibly variability because of as yet unknown pathophysiological differences among patients. This variability has been shown with vasopressin and propranolol, drugs used for the acute control and prevention of variceal bleeding respectively. It is now accepted that both these drugs have some therapeutic effect despite the variability in haemodynamic responses. As mentioned above, the therapeutic effect with vasopressin is modest and accompanied by many side effects. With propranolol, the therapeutic effect on rebleeding is also modest but with no serious side effects. In a primary prophylactic study, patients taking propranolol (or placebo) who did not reduce their hepatic venous pressure gradient to less than 12 mm Hg were shown to have more chance of bleeding. 53 The second consideration is that the dosage schedules of somatostatin in both research protocols and clinical studies have been largely empirical, usually giving a single bolus followed by an infusion. The third consideration is that the effects of somatostatin or octreotide and other vasoactive drugs during variceal bleeding may be quantitatively different from those seen in stable cirrhotic patients reported in haemodynamic studies, as patients present a different haemodynamic profile when bleeding, both in the splanchnic and systemic circulation, in comparison with stable patients. Thus, evidence for therapeutic efficacy must be sought in the results of clinical trials.
There are several trials that have compared somatostatin and octreotide with other treatment for acute variceal bleeding'5 16 tEfficacy was also assessed in a third group given combined somatostatin and balloon tamponade.
contrasting results (Table) .59 60 The trial by Valenzuela et al 59 suggests somatostatin is no more effective than placebo. The fact, however, that only 84 evaluable patients were recruited over 14 months in 1 1 centres shows a severe selection of patients. It is not clear from the paper how this occurred. The 83% placebo response rate is the highest reported in published works irrespective of the definition used to describe response. In the Royal Free study60 particular attention was taken to guard against biases of differing intervals to trial entry and severity of bleeding. A statistically significant benefit of somatostatin in controlling variceal bleeding compared with placebo was shown when given over a five day period. Failure to control bleeding over this interval occurred in 59% of the placebo group and 35% of the somatostatin group and transfusion requirements were halved (p=0025 (Table) there were no statistical differences in either efficacy or mortality and the results were virtually identical. As already mentioned, however, every trial apart from that by Walker et al163 had a statistically significant reduction in complication rate in the groups treated with somatostatin or octreotide. In the three trials v balloon tamponade (one with octreotide) 54 56 57 there was no statistically significant difference in efficacy or mortality. In the group of four trials v sclerotherapy,58 61 65 66 there was no statistical difference in efficacy or mortality between somatostatin or octreotide and injection sclerotherapy. Moreover, a recent trial of octreotide v sclerotherapy by Sung et al,64 performed in a skilled endoscopic unit, showed no differences in control of bleeding, early rebleeding, blood product use, or mortality between the two treatments.
Given that emergency sclerotherapy is now commonly used to control variceal bleeding irrespective of concomitant vasoactive treatment, it is reasonable to use it for active bleeding at endoscopy, as it permits a therapeutic measure to be given at initial diagnostic endoscopy. Indeed the Athens 1992 meta analysis (Burroughs, unpublished The clinical trials performed to date suggest that both octreotide and somatostatin are at least as effective as the conventional vasoactive drugs, balloon tamponade, and injection sclerotherapy in the treatment of variceal haemorrhage with the advantage of fewer side effects. Thus, they represent the best vasoactive agents pending further trials. Most importantly, however, these drugs need to be assessed as adjuvant treatment to emergency sclerotherapy for active bleeders. group.bmj.com on October 30, 2017 -Published by http://gut.bmj.com/ Downloaded from
